IMU - Imuniti - Imuniti obtains ethics approval to
IMU
IMU
IMU - Imuniti - Imuniti obtains ethics approval to commence a clinical
trial on its flagship product.
IMUNITI HOLDINGS LIMITED
(Registration number 2004/002282/06)
(JSE Code: IMU & ISIN: ZAE000089199)
("Imuniti" or "the Company")
IMUNITI OBTAINS ETHICS APPROVAL TO COMMENCE A CLINICAL TRIAL ON ITS
FLAGSHIP PRODUCT.
Further to the SENS announcement dated 17 April. Approval has been granted
by the South African Medical Research Council`s Ethics Committee to
commence trials on the Imuniti Wellness Pack. The Protocol title being "A
Phase 1 safety clinical trial of the herbal-nutritional supplement
(IMUNITI) with putative-modulating properties"
Pretoria
19 June 2007
DESIGNATED ADVISER:
EXCHANGE SPONSORS (PTY) LIMITED
Date: 19/06/2007 15:55:01 Produced by the JSE SENS Department.
Profile Group (Pty) Ltd. has taken care in preparing all information on this website, but does not accept any liability for errors or out-of-date information.
